Skip to main content

Market Trends & Strategy

Pharma Pressures Mount as TrumpRx and DTC Drug Pricing Models Face Economic and Policy Scrutiny

Image
Pharma Pressures Mount as TrumpRx and DTC Drug Pricing Models Face Economic and Policy Scrutiny

SHERIDAN, WYOMING - November 13, 2025 - As the federal government prepares to launch its TrumpRx direct-to-consumer platform in early 2026, U.S. drugmakers are accelerating their own discount initiatives in anticipation of sweeping pricing reforms tied to the Most Favored Nation (MFN) framework. Yet analysts and health economists warn that these programs-ranging from discounted dermatology creams to multi-billion-dollar GLP-1 therapies-may have limited influence on overall spending, with most insured patients unlikely to shift away from existing payer pathways.

Amgen's Repatha Clinical Breakthrough Strengthens Case for Earlier Cardiovascular Prevention

Image
Amgen Launches Direct-to-Patient Repatha Program to Expand Access and Reduce Out-of-Pocket Costs

SHERIDAN, WYOMING - November 13, 2025 - Amgen has released detailed Phase 3 data that could reshape how health systems approach primary prevention of cardiovascular events. The VESALIUS-CV results show that adding Repatha to standard lipid-lowering therapy significantly reduces major adverse cardiovascular events (MACE) in high-risk adults with no prior history of heart attack or stroke-an evidence base that could expand eligibility criteria, support more assertive LDL-C management strategies, and influence payer and provider adoption models across the U.S. and abroad.

Amgen Launches Direct-to-Patient Repatha Program to Expand Access and Reduce Out-of-Pocket Costs

Image
Amgen Launches Direct-to-Patient Repatha Program to Expand Access and Reduce Out-of-Pocket Costs

SHERIDAN, WYOMING - November 13, 2025 - Amgen has introduced a new U.S. direct-to-patient model that aims to make Repatha more affordable and accessible to adults at elevated cardiovascular risk. The initiative, called AmgenNow, offers a nearly 60% price reduction and removes common payer-driven barriers-an unusual move in the cardiometabolic market and one that could ripple across manufacturers, payers, and care-delivery partners seeking more predictable access pathways.

Amgen's VESALIUS-CV Data Push Repatha Into Earlier Cardiovascular Prevention

Image
Amgen’s VESALIUS-CV Data Push Repatha Into Earlier Cardiovascular Prevention

SHERIDAN, WYOMING - November 13, 2025 - Amgen's landmark VESALIUS-CV trial is redefining where PCSK9 inhibition fits in cardiovascular care, showing that Repatha can significantly cut major events even in high-risk adults who have never had a heart attack or stroke. For hospital systems, cardiology networks, and payers, the findings strengthen the case for treating low-density lipoprotein cholesterol (LDL-C) much more aggressively and much earlier in the patient journey.

Amgen's Repatha Data Signals a Potential Shift Toward Earlier Preventive Cardiology

Image
Amgen’s Repatha Data Signals a Potential Shift Toward Earlier Preventive Cardiology

Here is your fully rewritten, SEO-savvy B2B article following all rules of the updated prompt (no meta, no keywords, no watermarking, no duplication, 500-650 words, bolded H5-style subheads only, one verbatim quote used exactly as provided).

Amgen's Repatha Data Signals a Potential Shift Toward Earlier Preventive Cardiology

SHERIDAN, WYOMING - November 13, 2025 - New Phase III data from Amgen's VESALIUS-CV study are accelerating industry conversations around earlier preventive intervention in cardiology, with the company positioning Repatha as the first PCSK9 inhibitor to demonstrate event reduction in high-risk adults without a prior heart attack or stroke. For hospital systems, cardiology practices, and value-based care organizations, the findings add fresh momentum to a class of therapies long debated for their adoption challenges.

Neustart Krankenhauspolitik: Germany's Hospital Reform Summit Calls for Courage and Collaboration

Image
Neustart Krankenhauspolitik: Germany’s Hospital Reform Summit Calls for Courage and Collaboration

SHERIDAN, WYOMING - November 13, 2025 - At the upcoming Deutscher Krankenhaustag in Düsseldorf, political leaders, healthcare executives, and hospital associations will converge under the banner "Neustart Krankenhauspolitik - Mut zur Veränderung" to debate the direction of Germany's hospital reform agenda. The opening day, held on November 17, 2025, will set the tone for a year of pivotal decisions on financing, structural modernization, and system resilience.

Political and Financial Renewal in Focus

The program begins with a high-profile policy session featuring statements from Federal Health Minister Nina Warken (CDU) and North Rhine-Westphalia Health Minister Karl-Josef Laumann (CDU), joined by Bundestag and state representatives across party lines. The shared message: Germany's hospital landscape demands bold structural change to secure long-term care delivery and financial stability.

Deutscher Krankenhaustag 2025 Sets New Course for Hospital Reform, Nursing Innovation, and Global Collaboration

Image
Deutscher Krankenhaustag 2025 Sets New Course for Hospital Reform, Nursing Innovation, and Global Collaboration

SHERIDAN, WYOMING - November 13, 2025 - Germany's flagship hospital congress, the Deutscher Krankenhaustag 2025, will bring together policymakers, healthcare executives, and clinical leaders in Düsseldorf from November 17-20 to debate the country's most ambitious health system reforms in decades. Under the banner "Neustart Krankenhauspolitik - Mut zur Veränderung," the four-day event will focus on financing, digital transformation, workforce resilience, and international cooperation in the hospital sector.

Policy and Financing Take Center Stage
The congress opens on November 17 with a high-level political session featuring Federal Health Minister Nina Warken and NRW Health Minister Karl-Josef Laumann. Discussions will address hospital financing reform, long-term structural modernization, and the future of care provision across Germany's regional health landscape.

Moderna Narrows Losses as Cost-Cutting Strategy Begins to Stabilize Financial Outlook

Image
Moderna Narrows Losses as Cost-Cutting Strategy Begins to Stabilize Financial Outlook

SHERIDAN, WYOMING - November 10, 2025 - Moderna's latest quarterly report signals cautious optimism for the biotech sector, as the company's cost-reduction campaign shows measurable progress in curbing financial losses. The mRNA innovator reported a $200 million net loss for the third quarter-its fourth consecutive decline-but markedly smaller than previous quarters. Executives emphasized that the company is regaining operational balance through disciplined expense management and diversification beyond COVID-19 vaccines.

Cost Discipline Accelerates Turnaround Momentum

After steep losses of $1 billion in the first quarter and $800 million in the second, Moderna's third-quarter results demonstrate its most significant improvement to date. The company's leadership attributes the recovery to a sweeping cost-cutting plan that has exceeded expectations.

Branchentag Holz 2025: Cologne’s timber trade hub returns with market insights, “Neues Bauen” focus, and the GD Holz Forum

Image
Branchentag Holz 2025: Cologne’s timber trade hub returns with market insights, “Neues Bauen” focus, and the GD Holz Forum

SHERIDAN, WYOMING – November 4, 2025 – Germany’s flagship timber trade gathering, Branchentag Holz, returns to Koelnmesse on November 11–12, 2025, bringing wood wholesalers, manufacturers, service providers, and suppliers together for two days of deal-making, policy dialogue, and product discovery. With exhibition, conference, and awards under one roof, the event is positioned as a high-value stop for procurement teams and executives planning 2026 assortments, partnerships, and sustainable construction strategies.

Event at a glance: format, venue, hours
The 18th edition is staged in Cologne (Koelnmesse, Hall 8, North Entrance) and runs Tuesday 09:00–18:00 and Wednesday 09:00–16:00. The concept blends a compact two-day trade fair with the GD Holz Forum conference, enabling visitors to move seamlessly from technical sessions to supplier meetings and back to the show floor.

BHB Congress 2025 sets DIY retail agenda: AI modernization, circular economy, and decarbonisation take center stage

Image
BHB Congress 2025 sets DIY retail agenda: AI modernization, circular economy, and decarbonisation take center stage

SHERIDAN, WYOMING – November 1, 2025 – The 26th International BHB Congress will convene Germany’s DIY and home improvement leaders at the World Conference Center Bonn on November 26–27, 2025, pairing board-level strategy sessions with hands-on masterclasses spanning AI, logistics, retail media, and circular economy. A gala aboard the MS RheinMagie on November 26 includes the presentation of the DIY-Lifetime Award, underscoring the event’s status as the sector’s flagship gathering.